We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$87.3M
Cap. Flow
-$105M
Cap. Flow %
-9.42%
Top 10 Hldgs %
48.85%
Holding
77
New
7
Increased
18
Reduced
19
Closed
8

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$29.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$15.7M
3
TVTX icon
Travere Therapeutics
TVTX
+$15.4M
4
ACOR
Acorda Therapeutics
ACOR
+$15M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.1M

Top Sells

Rank Stock Value
1
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$41.1M
2
NVRO
NEVRO CORP.
NVRO
+$30.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.6M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$21.8M
5
ANGO icon
AngioDynamics
ANGO
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 84.53%
2 Financials 0.24%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
51
CALL
Heron Therapeutics
HRTX
$86.3M
$5.17M 0.46%
+300,000
New +$5.57M
PCRX icon
52
Pacira BioSciences
PCRX
$1.02B
$5.16M 0.46%
150,680
+57,300
+61% +$2.24M
PCRX icon
53
CALL
Pacira BioSciences
PCRX
$1.02B
$5.13M 0.46%
+150,000
New +$5.88M
ARCT icon
54
Arcturus Therapeutics
ARCT
$157M
$5.06M 0.45%
292,493
+70,049
+31% +$2.26M
TENX icon
55
Tenax Therapeutics
TENX
$385M
$4.56M 0.41%
62
– –
NVET
56
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$4.22M 0.38%
1,017,255
+17,255
+2% +$81.8K
MDWD icon
57
MediWound
MDWD
$183M
$4.09M 0.37%
75,855
– –
ANTH
58
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.64M 0.33%
144,334
– –
CFRX
59
DELISTED
ContraFect Corporation
CFRX
$3.54M 0.32%
1,786
+970
+119% +$1.9M
TRVN
60
DELISTED
Trevena, Inc.
TRVN
$3.32M 0.3%
787
– –
TRUP icon
61
Trupanion
TRUP
$1.05B
$2.68M 0.24%
+158,600
New +$2.43M
TNDM icon
62
Tandem Diabetes Care
TNDM
$1.17B
$2.56M 0.23%
+33,430
New +$2.44M
WINT
63
DELISTED
Windtree Therapeutics Inc
WINT
$1.99M 0.18%
777,797
– –
CDTX
64
DELISTED
Cidara Therapeutics
CDTX
$1.91M 0.17%
8,344
– –
DXTR
65
DELISTED
Dextera Surgical Inc.
DXTR
$1.59M 0.14%
844,167
-18,332
-2% -$39K
CASM
66
DELISTED
CAS Medical Systems, Inc.
CASM
$972K 0.09%
562,030
-248,822
-31% -$432K
PHIO icon
67
Phio Pharmaceuticals
PHIO
$12.1M
$585K 0.05%
5
-3
-38% -$405K
SSKN
68
DELISTED
Strata Skin Sciences
SSKN
$510K 0.05%
19,228
– –
PLX icon
69
Protalix BioTherapeutics
PLX
$191M
– –
-202,527
Closed -$1.3M
AIXC
70
AIxCrypto Holdings Inc
AIXC
$16.6M
– –
-6
Closed -$1.18M
SPY icon
71
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-550,000
Closed -$115M
TNXP icon
72
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– -$863K
PLXP
73
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-5,597
Closed -$444K
ENDP
74
CALL
DELISTED
Endo International plc
ENDP
– –
-200,000
Closed -$3.12M
GHDX
75
DELISTED
Genomic Health, Inc.
GHDX
– –
-270,400
Closed -$7M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Broadfin Capital held 77 positions worth $1.12B, up 8.5% from $1.03B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Broadfin Capital withdrew a net $105M in Q3 2016, closing 8 positions and reducing 19 holdings. Its most notable exit was Genomic Health, Inc., an estimated $7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 73% a quarter earlier, followed by Financials and Technology.

Against the trend, Broadfin Capital opened a new position in Teva Pharmaceuticals worth $13.8M.

  • Broadfin Capital's largest Q3 2016 buy was Teva Pharmaceuticals: 300,000 shares worth $13.8M.
  • Broadfin Capital added most to Heron Therapeutics in Q3 2016, an estimated $29.7M increase.
  • Broadfin Capital's biggest Q3 2016 reduction was RAPTOR PHARMACEUTICAL CORP COM STK (DE), cutting an estimated $41.1M.
  • Broadfin Capital fully exited Genomic Health, Inc. in Q3 2016, selling an estimated $7M.
  • Broadfin Capital's ten largest holdings make up 49% of its $1.12B portfolio in Q3 2016.
  • Broadfin Capital opened 7 new positions and closed 8 in Q3 2016.
  • Broadfin Capital's portfolio value rose 8.5% quarter-over-quarter to $1.12B.

Based on Broadfin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.